Normalized QRS Duration by LV Dimension
JACC: Clinical Electrophysiology · 2026
DOI: 10.1016/j.jacep.2026.01.032 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JACC: Clinical Electrophysiology, 2026. Verfasst von Enrui Zhang und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, First Affiliated Hospital, Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Cardiac Resynchronization Therapy, Heart Failure, Heart Ventricles. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Major Science and Technology Projects of China.
Abstract (Originalsprache)
BACKGROUND: Increasing evidence shows sex-specific differences in the efficacy of cardiac resynchronization therapy (CRT). Without a clear cardiac rationale, relying solely on sex to evaluate resynchronization outcomes is insufficient. OBJECTIVES: This study sought to assess whether QRS duration (QRSd) normalized to cardiac size (QRSd/left ventricular end-diastolic dimension [QRSd/LVEDD]) could underlie the observed sex-specific differences in resynchronization efficacy and guide CRT implantation. METHODS: This multicenter retrospective study screened 602 patients with heart failure who underwent biventricular or left bundle branch area pacing for resynchronization therapy. The primary composite outcome included all-cause mortality, heart failure hospitalizations, and ventricular tachyarrhythmic events. Interaction analysis and structural equation modeling were applied to evaluate whether QRSd/LVEDD could independently predict outcomes and elucidate sex-specific differences. RESULTS: Compared with male patients, female patients (n = 216) had a higher QRSd/LVEDD ratio (2.66 vs 2.48; P < 0.001). After QRSd/LVEDD adjustment, female patients no longer exhibited greater left ventricular ejection fraction improvement. Sex-specific differences initially observed in clinical outcomes (HR: 1.71; 95% CI: 1.17-2.48; P = 0.005) were eliminated by QRSd/LVEDD (HR: 1.14; 95% CI: 0.76-1.69; P = 0.527), with a significant dose-response relationship (P < 0.001). QRSd/LVEDD also stratified prognosis within each sex group (P < 0.001). No sex-specific differences were found among patients with the same QRSd/LVEDD (QRSd/LVEDD ≥2.55, P = 0.744; QRSd/LVEDD
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, First Affiliated Hospital, Nanjing Medical University, Nanjing, China.
- Montefiore Medical Center, Bronx, New York, USA.
- Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing, China.
- Department of Cardiology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
- Sichuan Provincial People's Hospital, Chengdu, China.
- Fujian Medical University Union Hospital, Fuzhou, China.
Förderung
- National Natural Science Foundation of China
- National Major Science and Technology Projects of China
Zitieren
APA
Zhang, E., Zeng, J., Zou, F., Fan, X., Huang, W., Tang, Y., Fu, F., Cai, B., Zheng, L., Gu, K., Shan, Q., Chen, K., Gu, M., Malik, S. U., Jacobs, S. A., Vijayaraman, P., Gold, M. R., Ellenbogen, K. A., & Zou, J. (2026). Normalized QRS Duration by LV Dimension. JACC: Clinical Electrophysiology. https://doi.org/10.1016/j.jacep.2026.01.032
Vancouver
Zhang E, Zeng J, Zou F, Fan X, Huang W, Tang Y, et al. Normalized QRS Duration by LV Dimension. JACC: Clinical Electrophysiology. 2026. doi:10.1016/j.jacep.2026.01.032
BibTeX
@article{Zhang2026,
author = {Zhang, Enrui and Zeng, Jiaxin and Zou, Fengwei and Fan, Xiaohan and Huang, Weijian and Tang, Yijia and Fu, Fayuan and Cai, Binni and Zheng, Liangrong and Gu, Kai and Shan, Qijun and Chen, Keping and Gu, Min and Malik, Saad U and Jacobs, Steven A and Vijayaraman, Pugazhendhi and Gold, Michael R and Ellenbogen, Kenneth A and Zou, Jiangang},
title = {Normalized QRS Duration by LV Dimension},
journal = {JACC: Clinical Electrophysiology},
year = {2026},
doi = {10.1016/j.jacep.2026.01.032}
}
EUVIMED